DexCom, Inc. (NASDAQ:DXCM) Stock Position Raised by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 0.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,857,286 shares of the medical device company’s stock after buying an additional 9,421 shares during the quarter. DexCom comprises 1.3% of Westfield Capital Management Co. LP’s investment portfolio, making the stock its 11th largest holding. Westfield Capital Management Co. LP’s holdings in DexCom were worth $230,471,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Skopos Labs Inc. bought a new position in DexCom during the fourth quarter valued at about $274,000. Congress Wealth Management LLC DE increased its holdings in shares of DexCom by 529.5% during the 4th quarter. Congress Wealth Management LLC DE now owns 167,705 shares of the medical device company’s stock valued at $20,811,000 after acquiring an additional 141,065 shares during the last quarter. Orion Portfolio Solutions LLC raised its stake in shares of DexCom by 3.4% in the 4th quarter. Orion Portfolio Solutions LLC now owns 7,483 shares of the medical device company’s stock valued at $970,000 after acquiring an additional 247 shares in the last quarter. Team Hewins LLC acquired a new stake in DexCom in the 4th quarter worth approximately $307,000. Finally, SageView Advisory Group LLC bought a new stake in DexCom during the fourth quarter worth approximately $344,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the sale, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at $8,611,765. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The disclosure for this sale can be found here. Insiders sold 186,641 shares of company stock valued at $25,217,707 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Raymond James boosted their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Citigroup increased their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $1.77 during trading hours on Friday, reaching $127.37. The stock had a trading volume of 2,274,964 shares, compared to its average volume of 2,872,973. The company has a market cap of $50.65 billion, a price-to-earnings ratio of 82.17, a PEG ratio of 3.19 and a beta of 1.23. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The business’s fifty day moving average is $132.96 and its two-hundred day moving average is $124.23. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, research analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.